EAU 2014 - Poster: Consistent long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: Final results of repeated treatments up to 4 years

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Gilles Karsenty,¹ Heinrich Schulte-Baukloh,² Roger Dmochowski,³ Karen Ethans,⁴ Brenda Jenkins,⁵ Steven Guard,⁶ Ho-Jin Lee,⁷ Michael Kennelly⁸ at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

¹Aix-Marseille Université, Marseille, France; ²St. Hedwig-Krankenhaus, Berlin, Germany; ³Vanderbilt University Medical Center, Nashville, TN, USA; ⁴University of Manitoba, Winnipeg, Canada; ⁵Allergan, Inc., Irvine, CA, USA; ⁶Allergan, Ltd., Marlow, UK; ⁷Allergan, Inc., Bridgewater, NJ, USA; ⁸Carolinas Medical Center, Charlotte, NC, USA